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a b s t r a c t
Despite about two decades of research in the ﬁeld of endocrine active compounds, still no validated human
recombinant (hr) estrogen receptor-␣ (ER␣) binding assay is available, although hr-ER␣ is available from
several sources. In a joint effort, US EPA and Bayer Schering Pharma with funding from the EU-sponsored
6th framework project, ReProTect, developed a model protocol for such a binding assay. Important features of this assay are the use of a full length hr-ER␣ and performance in a 96-well plate format. A
full length hr-ER␣ was chosen, as it was considered to provide the most accurate and human-relevant
results, whereas truncated receptors could perform differently. Besides three reference compounds [17␤estradiol, norethynodrel, dibutylphthalate] nine test compounds with different afﬁnities for the ER␣
[diethylstilbestrol (DES), ethynylestradiol, meso-hexestrol, equol, genistein, o,p -DDT, nonylphenol, nbutylparaben, and corticosterone] were used to explore the performance of the assay. Three independent
experiments per compound were performed on different days, and dilutions of test compounds from
deep-frozen stocks, solutions of radiolabeled ligand and receptor preparation were freshly prepared for
each experiment. The ER␣ binding properties of reference and test compounds were well detected. As
expected dibutylphthalate and corticosterone were non-binders in this assay. In terms of the relative
ranking of binding afﬁnities, there was good agreement with published data obtained from experiments
using a human recombinant ER␣ ligand binding domain. Irrespective of the chemical nature of the compound, individual IC50 -values for a given compound varied by not more than a factor of 2.5. Our data
demonstrate that the assay was robust and reliably ranked compounds with strong, weak, and no afﬁnity for the ER␣ with high accuracy. It avoids the manipulation and use of animals, i.e., the preparation
of uterine cytosol as receptor source from ovariectomized rats, as a recombinant protein is used and
thus contributes to the 3R concept (reduce, replace, and reﬁne). Furthermore, in contrast to other assays,
this assay could be adjusted to an intermediate/high throughput format. On the whole, this assay is a
promising candidate for further validation.
© 2010 Elsevier Inc. All rights reserved.

1. Introduction
There is concern that man-made and natural compounds may
interfere with the endocrine system and thus may affect wildlife
and humans and/or their progeny. Initial studies focused on interactions with estrogen receptor (ER)-mediated signaling and date
back to the 1980s [see 1]. These studies have intensiﬁed over the
years and have been used to characterize a number of chemicals
and natural products as compounds with weak estrogenic proper-
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ties. More recently, interactions with other receptors such as the
androgen receptor have gained attention [2–4]. Both the recommendations to the US Environmental Protection Agency (EPA) by
their Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) [5] and the OECD conceptual framework for
the testing and assessment of endocrine disrupting chemicals [6]
recognized receptor binding assays as important tools to study
interactions with sex hormone receptors. These assays, therefore,
represent important components of the US EPA tier 1 screening
battery and level 2 of the OECD’s conceptual framework. Interestingly, despite two decades of research in the ﬁeld of endocrine
active compounds and the availability of human recombinant ER
from several sources, no validated human recombinant ER bind-
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ing assay is available. In a joint effort, US EPA and Bayer Schering
Pharma (BSP) (with funding from the European Union-sponsored
6th framework project, ReProTect), developed a model protocol.
Additional advisement to this activity was given from an international expert group working on the validation of recombinant
ER and AR binding assays under the auspices of the OECD’s Validation Management Group for Non-Animal Testing (VMG-NA).
Important features of the protocol for competitive binding studies were the use of (a) a commercially available full length human
recombinant (hr) estrogen receptor-␣ (ER␣), (b) [3 H]-␤-estradiol
(1 nM) as ligand, (c) an amount of ER␣ resulting in a speciﬁc binding corresponding to approximately 20 ± 5% relative to the added
[3 H]-ligand, and (d) a 96-well plate format that allows feasibility for up to nine chemicals to be tested at a time (not including
the reference chemicals). A full length hr-ER␣ was chosen, as it
was considered to provide the most accurate and human-relevant
results, whereas as truncated receptor could perform in a different
manner. A commercially available full length hr-ER␣ was considered helpful for people not experienced in the isolation of receptors,
not having the equipment to grow (human) cells prior to isolation,
or that do not want to use animals for the preparation of receptors.
A set of reference (17␤-estradiol, a strong binder; norethynodrel,
a weak binder; and dibutylphthalate, a non-binder) and test compounds (diethylstilbestrol (DES), ethynylestradiol, meso-hexestrol,
equol, genistein, o,p -DDT, nonylphenol, n-butylparaben, and corticosterone) that had been agreed upon by a Chemical Advisory
Board (CAB) jointly appointed by the hr-ER␣ binding assay validation working group of the OECD’s VMG-NA (see above) was used
to explore the performance of the assay by evaluating a variety of
chemical classes and differing afﬁnities for the receptor. Results
were subjected to an independent statistical analysis. The outcome
of this effort is reported herein.
2. Materials and methods
2.1. Estrogen receptor-˛
Full length human recombinant estrogen receptor-␣ was obtained from Invitrogen Corporation (Carlsbad, CA, USA) (order no. P2187, lot no. 34216I). Functional
receptor concentration according to the manufacturer was 2088 pmol/mL with a
speciﬁc activity of 8700 pmol/mg. The receptor preparation was slowly thawed on
ice, and aliquots (20 pmol receptor) were placed in microvials, rapidly frozen in
liquid nitrogen and kept deep-frozen at −80 ◦ C. Aliquots were thawed only once.
2.2. Chemicals
17ß-Estradiol (CAS 50-28-2) 98%, 17␣-ethynylestradiol (57-63-6) 98%, diethylstilbestrol (DES, 56-53-1) 99%, m-hexestrol (84-16-2) 98%, dibutylphthalate,
dl-dithiothreitol (DTT) >99%, leupeptin semi-sulfate, bovine serum albumin (BSA),
and dextran-coated charcoal was supplied by Sigma–Aldrich (Taufkirchen, Germany). Nonylphenol (84852-15-3) 96.9% and corticosterone (50-22-6) 98.5% were
obtained from Fluka (Buchs, Switzerland) through Sigma–Aldrich. Racemic equol
(531-95-3) 98.2% was delivered by Apin Chemicals (Abingdon, UK), 1,1,1-trichloro2,2-bis(o,p -chlorophenyl)ethane (o,p -DDT, 789-02-6) 99.2% was purchased from
Supelco (Bellefonte, PA, USA) through Sigma–Aldrich. Norethynodrel (68-23-5,
United States Pharmacopial Convention) 100%, genistein (446-72-0, American
Custom Chemical Corp.) 99.16%, and n-butylparaben (94-26-8, ChemService)
98.2% were kindly provided by U.S. EPA. Tris(hydroxymethyl)aminomethane p.a.,
anhydrous glycerol, ethanol p.a. and DMSO p.a. were supplied by E. Merck (Darmstadt, Germany). Ultima Flo APTM and Ultima Gold scintillation cocktails were
products of Canberra-Packard (Frankfurt, Germany). [3 H]-17␤-estradiol (estradiol
[2,4,6,7,16,17␤-3 H(N)], speciﬁc activity: 4.07 TBq/mmol, 37 MBq/mL) in ethanol
with a radiochemical purity of >97% was supplied by PerkinElmer (RodgauJürgesheim, Germany).
2.3. Determination of receptor binding
Receptor binding experiments were performed in 96-well microtiter plates in
at least triplicate incubations. Assay buffer (0.2 mM leupeptin, 2 mmol DTT, 10 g
BSA and 100 mL glycerol made up to 1 L with 10 mM Tris–HCl; pH 7.5) was freshly
prepared for each experiment prior to incubation. Stock solutions of reference
compounds 17␤-estradiol (10 mM), norethynodrel (10 mM), and dibutylphthalate
(100 mM) and test compounds (100 mM) were prepared in ethanol, if 100 mM could
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not be achieved, DMSO was used, also for the determination of concurrent total and
non-speciﬁc binding. Aliquots of stock solutions were kept deep-frozen at −80 ◦ C,
and each aliquot was used only once and discarded at the end of an individual experiment. Serial dilutions of stocks in solvent were made, then diluted into assay buffer
1:50 as the ﬁnal step. [3 H]-ligand solution (4 nM if not otherwise indicated resulting in a ﬁnal concentration of 1 nM) was prepared in assay buffer. Similarly ER␣ was
dissolved in assay buffer. To study receptor binding, assay buffer (80 L) containing test compound or solvent (2%) was mixed with 40 L [3 H]-ligand solution for
10–15 min at 2–8 ◦ C. Then, 40 L of ER␣ solution was added and the whole mixture
was incubated at 2–8 ◦ C overnight under slight (appr. 250 rpm) continuous shaking.
Following incubation overnight, 80 L of a 5% dextran-coated charcoal suspension
(the optimal percentage had been empirically determined) in cold assay buffer was
added. After mixing in the cold at 2–8 ◦ C for 10 min, charcoal was sedimented by
centrifugation at 4000 rpm for 5 min in a cooling centrifuge at 4 ◦ C. Finally, 50 L
aliquots of the clear supernatant containing the ER␣-ligand complex were placed in
another 96-well plate and mixed with 200 L Ultima Flo APTM scintillation cocktail
(Canberra-Packard, Frankfurt, Germany) and radioactivity was determined by LSC
using a LSC microplate reader (1450 MicrobetaTM Trilux, Wallac, Freiburg, Germany).
In all studies, the actual amount of ligand was determined by liquid scintillation counting (LSC) in a ␤-counter (1900 TR Counter, Canberra-Packard, Frankfurt,
Germany) with quench correction. The maximally tolerated deviation from the theoretical amount was 6%. If the tolerance was exceeded, depending on the deviation,
small volumes of buffer or small amounts of radiolabeled ligand were added to meet
the limits.
The amount of receptor as speciﬁed in the model protocol should result in a
speciﬁc binding roughly corresponding to 20 ± 5% relative to the added labeled
ligand under conditions of competitive binding, however, slight deviations would
be acceptable if not occurring regularly. Furthermore, non-speciﬁc binding under
these conditions should not exceed 35% of total binding. To determine the amount
of receptor necessary experimentally, ﬁnal concentrations of 0.25, 0.5, 0.75, and
1.0 nM ER␣ were incubated with 1 nM [3 H]-17␤-estradiol, and non-speciﬁc binding was determined in parallel in the presence of 1 M radioinert ligand. For each
condition six replicates were performed.
Saturation of the receptor was studied by incubating the receptor with
increasing ﬁnal concentrations (0.03, 0.06, 0.08, 0.10, 0.30, 0.60, 1.0, 3.0 nM) of [3 H]17␤-estradiol. Non-speciﬁc binding was determined in parallel in the presence of a
1000-fold molar excess of unlabeled 17␤-estradiol. All incubations were performed
in triplicate.
Studies on competitive binding were performed using a ligand concentration of
1 nM [3 H]-17␤-estradiol and had to be spread across several 96-well plates. On
the ﬁrst plate, ER␣ was incubated with the reference compounds 17␤-estradiol
(0.010, 0.10, 0.30, 1.0, 3.0, 10, 100, 1000 nM), norethynodrel (3.0, 30, 100, 300, 1000,
3000, 10,000, 30,000 nM), and dibutylphthalate (0.1, 1.0, 10, 100, 1000, 10 × 103 ,
100 × 103 , 1000 × 103 nM); furthermore, vehicle controls (no competitor), buffer
controls (no competitor, no solvent) and incubations for non-speciﬁc binding in the
presence of 1 M unlabeled 17␤-estradiol were performed. On the other plates, the
receptor was incubated with test compounds up to 1 mM (0.1, 1.0, 10, 100, 1000,
10 × 103 , 100 × 103 , 1000 × 103 nM), if possible.
In the course of this investigation, for each reference/test compound four independent competitive binding experiments (runs A–D) were performed. For solvent
controls, buffer controls, and non-speciﬁc binding six replicates were performed
each, incubations containing reference/test compounds were studied in triplicate.
Run D is the repetition of run C which was invalidated. The statistical analysis for
run C had consistently indicated a putative data error for all 12 compounds under
investigation, and in the light of a ligand concentration of 1 nM the IC50 -value for
estradiol of 0.08 nM was implausibly low.
2.4. Data handling
Using the data analysis program, Prism 5.02 (GraphPad Software, Inc., San Diego,
CA), a user deﬁned analysis titled “One site − Total + Non-Speciﬁc (NS) Binding,
accounting for ligand depletion” was performed and entered into Prism templates for all saturation binding runs. More information on the equation used
is available from the book by Motulsky and Christopoulos (2003), “Fitting models to biological data using linear and non-linear regression: a practical guide
to curve ﬁtting” GraphPad Software, Inc., San Diego, CA. Available online at:
http://www.graphpad.com/manuals/prism4/RegressionBook.pdf—page 210.
For competitive binding experiments, prior to ﬁtting a dose-response model
and estimation of IC50 -values mean non-speciﬁc binding was subtracted from binding observed for solvent and buffer controls or in the presence of reference/test
compounds to achieve the speciﬁc binding After subtraction speciﬁc binding in the
presence of reference/test compounds was divided by the mean speciﬁc binding of
the solvent control. The three-parametric log-logistic function
f (x) =

1
1 + exp(2 (log(x) − 3 ))

was ﬁtted to the transformed data using the drm function of R-package drc [7,8].
Parameter  1 is the upper asymptote of the response range and corresponds to
what is called “Top” in GraphPad Prism, parameter  2 is the slope parameter, and
parameter  3 corresponds to the log of the IC50 . Note that there is no estimation
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Fig. 1. Determination of the necessary receptor concentration–linear relationship
between speciﬁc binding and receptor concentration. Under conditions corresponding to competitive binding increasing ER␣ concentrations were incubated with 1 nM
[3 H]-17␤-estradiol. Non-speciﬁc binding was assessed in parallel in the presence
of 1 M unlabeled 17␤-estradiol. Following incubation overnight, unbound radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and
sedimentation of DBC by centrifugation. ER␣-bound radiolabel in the supernatant
was determined by liquid scintillation counting. Speciﬁc binding was calculated as
the difference of total and non-speciﬁc binding. For each condition six replicates
were performed. Means ± S.D. are given.

of the lower asymptote of the response range. The “Bottom” was assumed to be 0
after correction for non-speciﬁc binding in case of full displacement of ligand from
the receptor. In the context of receptor binding assays, the IC50 -value represents
the concentration of a test compound displacing 50% of receptor bound ligand. IC50 values and 95% conﬁdence intervals were calculated using the ED function of package
drc. This software program was also used to generate graphs of competitive binding
experiments.

3. Results
3.1. Determination of the necessary amount of receptor
The model protocol requested an amount of receptor resulting in a speciﬁc binding corresponding to 20 ± 5% of the added
ligand under conditions of competitive binding (i.e., 1 nM [3 H]17␤-estradiol). When increasing amounts of estrogen receptor-␣
were incubated with 1 nM [3 H]-17␤-estradiol in the absence and
presence of unlabeled 1 M 17␤-estradiol (to assess non-speciﬁc
binding), a linear relationship between total and speciﬁc binding and receptor concentration was obtained. Non-speciﬁc binding
was similar irrespective of the receptor concentration (Fig. 1). The
optimal range used for the following studies was at a receptor concentration of 0.5 nM, concomitant speciﬁc binding corresponding
to 23.1% of the added ligand (Table 1).
3.2. Saturation of estrogen receptor-˛ binding
To characterize the functionality of the receptor, saturation experiments were performed. Receptor was incubated with
increasing concentrations of [3 H]-17␤-estradiol, non-speciﬁc binding was assessed in the presence of 1000-fold molar excess of

Fig. 2. (A) Saturation binding data of the human recombinant full length estrogen
receptor-␣ utilizing [3 H]-17␤-estradiol. ER␣ (nominally 0.5 nM) was incubated with
increasing ﬁnal concentrations (0.03, 0.06, 0.08, 0.10, 0.30, 0.60, 1.0, 3.0 nM) of [3 H]17␤-estradiol (1 nM = 39,072 dpm). Non-speciﬁc binding was determined in parallel
in the presence of a 1000-fold molar excess of unlabeled 17␤-estradiol. For each condition three replicates were performed. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC)
and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand
in the supernatant was determined by liquid scintillation counting. Speciﬁc binding was calculated as the difference of total and non-speciﬁc binding Graphs were
generated using the non-linear regression software program Prism version 5.02.
The ﬁgure shows a representative experiment. (B) Scatchard analysis of the human
recombinant full length estrogen receptor-␣ utilizing [3 H]-17␤-estradiol. Data for
total and non-speciﬁc binding shown in (A) were analysed by Prism version 5.02
taking into account ligand depletion. The ﬁgure shows a representative experiment.

unlabeled 17␤-estradiol. Non-speciﬁc binding increased linearly
and moderately in relation to the [3 H]-17␤-estradiol concentration,
whereas total binding increased strongly and almost linearly up to
0.6 nM [3 H]-17␤-estradiol. At higher concentrations of [3 H]-17␤estradiol total binding was still rising, but at a slower rate. Speciﬁc
binding increased strongly and almost linearly up to 0.6 nM [3 H]17␤-estradiol, but at higher concentrations approached a plateau.
These ﬁndings correspond well with a fully functional receptor
showing saturable binding at higher ligand concentrations (Fig. 2).
Results of the Scatchard analysis of the saturation experiments are
given in Table 2. The observed mean Kd of 0.3734 nM is in the
reported range for the human ER␣ (see also Section 4), and the
Bmax of 0.3439 nM corresponds well to the added receptor concentration of 0.5 nM.

Table 1
Determination of the necessary receptor concentration.
Receptor concentration (nominal) [nM]
0.25
0.50
0.75
1.00

Mean speciﬁc binding (total incubation) [dpm]
4,874
9,029
12,635
16,151

Speciﬁc binding (relative to the nominally added ligand) [%]
12.5
23.1
32.3
41.3

The assay was performed under conditions corresponding to competitive binding, i.e., in the presence of 1 nM [3 H]-17␤-estradiol (nominally 39,072 dpm) and increasing ER␣
concentrations as indicated. Non-speciﬁc binding was assessed in parallel incubations containing 1 M unlabeled 17␤-estradiol. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the
supernatant was determined by liquid scintillation counting. Speciﬁc binding was calculated as the difference of total and non-speciﬁc binding. For each condition six
replicates were performed.
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Table 2
Scatchard analysis of saturation experiments.
Experiment No.

Kd [nM]

Bmax [nM]

1
2
3
Mean ± S.D.

0.3822
0.3851
0.3530
0.3734 ± 0.0178

0.3533
0.2992
0.3791
0.3439 ± 0.0408

ER␣ was incubated with increasing ﬁnal concentrations (0.03, 0.06, 0.08, 0.10, 0.30,
0.60, 1.0, 3.0 nM) of [3 H]-17␤-estradiol. Non-speciﬁc binding was determined in
parallel in the presence of a 1000-fold molar excess of unlabeled 17␤-estradiol. For
each condition three replicates were performed. Following incubation overnight,
unbound radiolabeled ligand was removed by absorption to dextran-bound charcoal
(DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled
ligand in the supernatant was determined by liquid scintillation counting. Three
independent experiments were run. Scatchard analysis was performed using Graph
Pad Prism 5.02 taking into account ligand depletion.

3.3. Competition experiments
General binding characteristics in the absence of competitor are
summarized in Table 3. In the presence of optimal ligand concentrations (99–101% of the nominal value) little variability for
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total, non-speciﬁc and speciﬁc bindings was observed across the
experiments. Speciﬁc binding for vehicle controls corresponded
to 22.6–29.8% of the theoretically added ligand, the corresponding coefﬁcient of variation across the six experiments was 12.2%.
Similar ﬁgures were obtained for speciﬁc binding for buffer controls (total binding in the absence of solvent minus non-speciﬁc
binding), however, there seemed to be a trend to higher values for
speciﬁc binding in DMSO controls compared to speciﬁc binding in
buffer controls. Mean non-speciﬁc binding corresponded to 15% of
total binding, accordingly, total binding mostly represented speciﬁc
binding to the receptor.
Standard solvent was ethanol, and with the exception of 17␤estradiol and norethynodrel, all compounds were considered for
testing up to 1 mM, an aim that could not always be achieved.
A ﬁnal concentration of 1 mM resulted in strong turbidity for
dibutylphthalate, DES, and ethynylestradiol, and in slight turbidity for m-hexestrol and nonylphenol. Genistein and corticosterone
could only be tested up to 100 M (ﬁnal conc.) due to their limited solubility in ethanol, whereas 100 M o,p -DDT still resulted
in turbidity. In order to potentially improve their solubility, genistein, o,p -DDT, and corticosterone together with the set of reference

Table 3
Receptor binding characteristics in competition experiments in the absence of competitor.
Experiment

Solvent

Ligand concentration
[% of nominal]

Binding [% of nominally added ligand]

Total

A
B
D
E
F
G

Ethanol
Ethanol
Ethanol
DMSO
DMSO
DMSO

100.6
99.9
100.2
99.1
101.3
99.3

Non-speciﬁc

Buffer

Solvent

30.75
26.88
34.76
24.21
23.43
29.18

30.33
27.86
35.01
26.33
27.70
33.77

4.35
4.02
5.26
3.71
4.55
4.34

Speciﬁc
Buffer

Solvent

26.40
22.86
29.50
20.50
18.88
24.84

25.98
23.85
29.75
22.62
23.15
29.43

ER␣ was incubated with 1.0 nM of [3 H]-17␤-estradiol in the presence or absence of 1% solvent as indicated. Non-speciﬁc binding was determined in parallel in the presence
of 1 M unlabeled 17␤-estradiol. For each condition six replicates were performed. Following incubation overnight, unbound radiolabeled ligand was removed by absorption
to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the supernatant was determined by liquid scintillation
counting. Three independent experiments were run for each solvent. Speciﬁc binding was calculated as the difference of total and non-speciﬁc binding. Corresponding mean
values are given.

Fig. 3. Competitive binding to the human recombinant full length estrogen receptor-␣ of reference and test compounds using ethanol as solvent. Receptor (nominally 0.5 nM)
was incubated with 1 nM [3 H]-17␤-estradiol and increasing concentrations of compounds as indicated. Following incubation overnight, unbound radiolabeled ligand was
removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in the supernatant was determined
by liquid scintillation counting. Binding was corrected for non-speciﬁc binding (NSB) and expressed relative to the corresponding solvent control. For the solvent control and
for NSB in the presence of 1 M 17␤-estradiol six replicates were performed, any other condition was studied in triplicate. Data correspond to run D. For the sake of clarity,
only the curve ﬁt, but no individual data points are given.
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4. Discussion

Fig. 4. Competitive binding to the human recombinant full length estrogen
receptor-␣ of reference and test compounds using DMSO as solvent. Receptor
(nominally 0.5 nM) was incubated with 1 nM [3 H]-17␤-estradiol and increasing concentrations of compounds as indicated. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC)
and sedimentation of DBC by centrifugation. Receptor-bound radiolabeled ligand in
the supernatant was determined by liquid scintillation counting. Binding was corrected for non-speciﬁc binding (NSB) and expressed relative to the corresponding
solvent control. Data correspond to run D. For the solvent control and for NSB in the
presence of 1 M 17␤-estradiol six replicates were performed, any other condition
was studied in triplicate. Data correspond to run F. For the sake of clarity, only the
curve ﬁt, but no individual data points are given.

compounds were also tested using DMSO as solvent. Corticosterone
and genistein could be dissolved in DMSO at 100 mM, but the
resulting ﬁnal concentration of 1 mM resulted in slight turbidity for
genistein. Similarly, ﬁnal concentrations of 1 mM dibutylphtalate
and 100 M o,p -DDT resulted in strong and slight (o,p -DDT) turbidity. Accordingly, only for corticosterone the use of DMSO ﬁnally
resulted in an improved solubility.
ER␣ binding data for all compounds dissolved in ethanol
expressed as IC50 -values are summarized in Table 4. Irrespective
of limited solubility in ethanol or in the ﬁnal assay, IC50 -values
could be observed for all reference and test compounds except for
dibutylphthalate and corticosterone that showed no afﬁnity to the
ER␣. A compilation of representative displacement curves using
ethanol as solvent is shown in Fig. 3. Corresponding relative binding
afﬁnities (IC50 of 17␤-estradiol divided by the IC50 of the test chemical and multiplied by 100) are given in Table 5. Genistein, o,p -DDT,
and corticosterone together with the set of reference compounds
were also tested using DMSO as solvent. A compilation of representative displacement curves using DMSO as solvent is given in
Fig. 4. Corresponding IC50 -values and relative binding afﬁnities are
presented in Tables 6 and 7.
Overall, the following rank order of afﬁnity to the ER␣ could be
established:
17␤-Estradiol > ethynylestradiol > DES > m-hexestrol > equol >
norethynyodrel > genistein ≈ nonylphenol > o,p DDT > butylparaben
Dibutylphthalate and corticosterone were characterized as nonbinders. The observed rank order of afﬁnity to the ER␣ was in line
with our expectations.

The value of receptor binding assays both as a mechanistic tool
to characterize receptor mediated endocrine activity, but also as an
important screening assay for endocrine active compounds, is well
recognized. Interestingly, after two decades of research in the ﬁeld
of endocrine active compounds, still no validated human recombinant (full length) ER␣ binding assay is available. Aim of this work
was to evaluate a model protocol as a ﬁrst step towards a validation
of a human recombinant full length ER␣ binding assay.
The model protocol worked well and the general requirements
were fulﬁlled: non-speciﬁc binding in competition experiments
was clearly below the maximally tolerated 35% of total binding
and speciﬁc binding roughly corresponded to 20 ± 5% relative to
the added [3 H]-17␤-estradiol for solvent controls. The upper limit
was occasionally slightly exceeded, but not on a regular basis
and thus was acceptable. Saturation experiments demonstrated
that at a ligand concentration of 1 nM binding the receptor was
still not saturated. This indicates that on the one hand competitors could readily displace [3 H]-17␤-estradiol from the ER␣, and
on the other hand the ligand concentration was high enough to
provide a readily measurable signal. Scatchard analysis of the saturation experiments provided a mean Kd of 0.3734 nM which is
well within the range of reported Kd values for full length human
recombinant ER␣ or ER isolated from human cells, whereas truncated recombinant ER␣ and possibly rat uterine ER may have higher
Kd values (see Table 8). The observed Bmax of 0.3439 nM corresponds well to the added 0.5 nM receptor protein (determined by
means of the hydroxyapatite methodology according to the manufacturer’s information) and indicates equivalence of the charcoal
and hydroxyapatite methodologies.
When competitive binding was studied, irrespective of the
chemical nature of the compound and the solvent used, for a given
compound individual IC50 -values varied by not more than a factor of 2.5 from one another. Variability of binding afﬁnities relative
to 17␤-estradiol (RBA) was in the same range, only for equol (2.9)
and genistein (3.3) slightly higher values were observed. In general
IC50 -values for runs A and B were more comparable to each other
than data from run D. However, there was no uniform trend, and
IC50 -values obtained in run D were either higher, lower, or comparable (n-butylparaben) to those in the other runs. No difference
in the quality of the data sets for run D was observed and IC50 values for run D maximally differed from those of runs A and B by
a factor of 2.2. This difference – in the absence of a trend – was
considered as random. Mean coefﬁcients of variation (CVs) across
all compounds were 25% (ethanol as solvent) and 13% (DMSO) for
IC50 -values and 24% (ethanol) and 13% (DMSO) for relative binding
afﬁnities. These low values, especially in light of the low number
of independent experiments, indicate that the assay is capable of
accurately assessing receptor afﬁnities with only small variability.
Following an ICCVAM/NICEATM recommendation [9] ethanol
was used as solvent whenever possible. Accordingly, only few
compounds, namely the reference compounds 17␤-estradiol,
norethynodrel, and dibutylphthalate as well as genistein, o,p -DDT,
and corticosterone were tested using both solvents. The use of
DMSO seemed to provide lower variability of the IC50 /RBA values and possibly slightly lower IC50 -values compared to the use
of ethanol. However, in the light of the low number of experiments
with DMSO and the small number of compounds studied, it is currently not possible to consider one solvent more appropriate than
the other. Basically, both solvents can be used with the assay, and
these options can be helpful to achieve optimal dissolution of test
compounds.
Optimal interactions of a ligand with its receptor requires that
the free ligand concentration is similar to the added concentration, i.e., total binding as the sum of speciﬁc and non-speciﬁc
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Table 4
IC50 -values achieved for reference and test compounds using ethanol as solvent.
Compound

Experiment

IC50 -value [nM]

17␤-Estradiol

A
B
D
Mean ± S.D.

1.297
1.301
0.965
1.188 ± 0.193

Norethynodrel

A
B
D
Mean ± S.D.

451.2
410.8
702.3
521.4 ± 157.9

Conﬁdence interval [nM]
Lower
1.1800
1.1880
0.8814

Coefﬁcient of variation [%]

Upper
1.425
1.425
1.057
16.2

408.2
366.1
623.9

498.6
460.8
790.6
30.3

a

A
B
D
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

17␣-Ethynylestradiol

A
B
D
Mean ± S.D.

1.939
2.508
1.294
1.914 ± 0.607

1.673
1.930
1.199

2.246
3.259
1.397

DES

A
B
D
Mean ± S.D.

7.961
7.723
5.550
7.078 ± 1.329

6.980
6.611
4.931

9.081
9.021
6.247

m-Hexestrol

A
B
D
Mean ± S.D.

34.62
36.07
16.02
28.90 ± 11.18

30.58
20.39
13.16

Equol, racemic

A
B
D
Mean ± S.D.

93.78
91.09
197.2
127.4 ± 60.50

75.03
67.00
180.0

Genistein

A
B
D
Mean

422.6
–b
1049
735.8

350.2
–
788.8

A
B
D
Mean ± S.D.

868.8
1024
859.8
917.5 ± 92.3

628.7
692.6
589.2

Dibutylphthalate

Nonylphenol



b

o,p -DDT

A
B
D
Mean

–
1333
2399
1866

n-Butylparaben

A
B
D
Mean ± S.D.

228.4 × 102
254.0 × 102
232.0 × 102
238.1 × 102 ± 13.85 × 102

Corticosterone

A
B
D
Mean ± S.D.

No afﬁnitya
No afﬁnity
No afﬁnity
–

–

31.7

18.8
39.18
63.81
19.50
38.7
117.2
123.8
216.0
47.5
509.9
–
1394
Not calculated
1201
1514
1255
10.1
–
950.0
1937

–
1872
2970
Not calculated

166.6 × 102
183.0 × 102
162.0 × 102

313.1 × 102
352.7 × 102
332.4 × 102
5.8

–

ER␣ (nominally 0.5 nM) was incubated with 1 nM [3 H]-17␤-estradiol and increasing concentrations of the indicated compounds. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. ER␣-bound radiolabel in the supernatant was
determined by liquid scintillation counting. Binding was corrected for non-speciﬁc binding (NSB) and expressed relative to the corresponding solvent control. For the solvent
control and NSB in the presence of 1 M 17␤-estradiol six replicates were performed, any other condition was studied in triplicate. IC50 -values were calculated by means of
the software R-package drc using a three-parametric log-logistic function. Results from three independent experiments A, B, and D are given.
a
Dibutylphthalate and corticosterone were tested up to 100 M.
b
No IC50 -value was calculated due to unclear dose response (displacement curves were comparable to corresponding experiments, but contained one or two aberrant
data points a low concentrations).

binding should not exceed 10%. However, assay miniaturization
in order to allow intermediate or high throughput, increases the
risk of ligand depletion (where the actual free ligand concentration
is signiﬁcantly lower than the added ligand concentration), since
receptor concentrations are rather high in these assays in order to
achieve adequate signal sizes [10]. In competition experiments, ligand depletion results in a shift of competition curves/IC50 -values
to the right, i.e., to higher concentrations [11]. With regard to the

experiments reported herein, total binding in vehicle controls of
competition experiments corresponded to 26–35% of the added ligand (see Table 3). Thus, in all experiments slight ligand depletion
had occurred. Modeling of ligand depletion [11] indicated that the
impact on competition experiments of a depletion up to 38% was
small. Accordingly, competition experiments reported herein was
sufﬁciently accurate in terms of ligand depletion and no corrective
action is needed. The use of relative binding afﬁnities with all com-
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Table 5
Relative binding afﬁnities for reference and test compounds using ethanol as solvent.
Compound

Experiment No.

Relative binding afﬁnity [%]

Coefﬁcient of variation [%]

100

–

Norethynodrel

A
B
D
Mean ± S.D.

0.2875
0.3167
0.1374
0.2472 ± 0.0962

38.9

Dibutylphthalate

A
B
D
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

–

A
B
D
Mean ± S.D.

66.89
51.87
74.57
64.45 ± 11.55

17.9

DES

A
B
D
Mean ± S.D.

16.29
16.85
17.39
16.84 ± 0.55

3.3

m-Hexestrol

A
B
D
Mean ± S.D.

3.746
3.607
6.024
4.459 ± 1.357

30.4

Equol, racemic

A
B
D
Mean ± S.D.

1.383
1.428
0.489
1.100 ± 0.530

48.2

Genistein

A
B
D
Mean

0.3069
–
0.0920
0.1995

Not calculated

A
B
D
Mean ± S.D.

0.1493
0.1271
0.1122
0.1295 ± 0.0186

14.4

o,p -DDT

A
B
D
Mean

–
0.0976
0.0402
0.0689

Not calculated

n-Butylparaben

A
B
D
Mean ± S.D.

0.00568
0.00512
0.00416
0.00499 ± 0.00077

15.4

Corticosterone

A
B
D
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

–

17␤-Estradiol

17␣-Ethynylestradiol

Nonylphenol



Relative binding afﬁnities were calculated from data given in Table 4.

pounds being tested under the same conditions should even further
minimize a small impact of ligand depletion.
An important step in the evaluation of an assay is the comparison of assay data with data from similar assays observed for the
same test compounds. In Table 9, results from the investigation
reported herein are compared to ER␣ binding data from several
sources. With regard to data generated for full length human
recombinant ER␣ [12,13] and for a human recombinant ER␣ ligand
binding domain as receptor source (by the Chemicals Evaluation
and Research Center (CERI) in Japan with funding by the Japanese
Ministry of Economy, Trade and Industry [14]), a good to very good
ﬁt for the binding relative to estradiol (RBA) was observed. For
compounds with weak afﬁnity to the ER␣ the concurrence was
excellent, and also for compounds with stronger afﬁnity, the ranking was comparable, although in absolute terms in our hands the
relative binding values for DES, ethynylestradiol and m-hexestrol
were lower mainly compared to the CERI data. A similar constellation was observed when comparing our RBAs with those observed

for rat uterine cytosol as receptor source [15,16]. It remains to be
elucidated further whether these lower RBAs are characteristic of
the human recombinant full length ER␣ as opposed to a human
truncated or rat receptor or are related to other reasons such as the
solvent used or assay buffer composition (e.g., in aqueous media
DES can be converted to its much weaker cis-isomer). If this was
the case for a large portion of DES, the lower RBA of DES could readily be explained [17]. The CERI assay utilized DMSO as the solvent in
all experiments, while this assay used EtOH as the solvent for DES.
Finally, as reported here and by others [14,15], dibutylphthalate
and corticosterone did not show afﬁnity for the ER␣.
On the whole, our data demonstrate that the assay was robust
and reliably ranked compounds with strong, weak, and without
afﬁnity for the ER␣ with high accuracy. Using a human recombinant full length estrogen receptor-␣, it avoids the manipulation
and use of animals, i.e., the preparation of uterine cytosol from
ovariectomized rats, and thus contributes to the 3R concept. Furthermore, in contrast to other assays, our assay could be adjusted
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Table 6
IC50 -values achieved for reference and test compounds using dimethylsulfoxide as solvent.
Compound

Experiment No.

IC50 -value [nM]

17␤-Estradiol

E
F
G
Mean ± S.D.

0.9857
0.8193
0.7654
0.8568 ± 0.1148

Norethynodrel

E
F
G
Mean ± S.D.

424.5
353.4
365.5
381.1 ± 38.0

Conﬁdence interval [nM]
Lower

Upper

0.8443
0.7280
0.6624

1.151
0.9220
0.8845
13.4

384.5
308.9
298.6

468.8
404.4
447.4
10.0

a

E
F
G
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

Genistein

E
F
G
Mean ± S.D.

744.5
776.4
633.1
718.0 ± 75.2

o,p -DDT

E
F
G
Mean ± S.D.

1405
1770
1225
1467 ± 278

Corticosterone

E
F
G
Mean ± S.D.

No afﬁnitya
No afﬁnity
No afﬁnity
–

Dibutylphthalate

Coefﬁcient of variation [%]

–
611.3
678.6
520.1

906.6
888.4
770.7
10.5.

1081
1339
923.6

1825
2340
1625
19.0

–

ER␣ (nominally 0.5 nM) was incubated with 1 nM [3 H]-17␤-estradiol and increasing concentrations of the indicated compounds. Following incubation overnight, unbound
radiolabeled ligand was removed by absorption to dextran-bound charcoal (DBC) and sedimentation of DBC by centrifugation. ER␣-bound radiolabel in the supernatant was
determined by liquid scintillation counting. Binding was corrected for non-speciﬁc binding (NSB) and expressed relative to the corresponding solvent control. For the solvent
control and NSB in the presence of 1 M 17␤-estradiol six replicates were performed, any other condition was studied in triplicate. IC50 -values were calculated by means of
the software R-package drc using a three-parametric log-logistic function. Results from three independent experiments E, F, and G are given.
a
Dibutylphthalate was tested up to 100 M, corticosterone up to 1 mM.

to an intermediate/high throughput format. In terms of the ECVAM
modular approach of validation, the data set presented herein
corresponds to the ﬁrst two modules, namely test deﬁnition and
within-laboratory variability [18]. Further testing of the protocol
in collaboration with OECD in additional laboratories is ongoing and will provide an in-depth evaluation of transferability and
inter-laboratory variability. The assay may be used to screen for

endocrine-modulating compounds with afﬁnity for the ER␣, to further investigate equivocal results from other in vitro assays such as
transactivation assays, and it may also be used as a mechanistic tool
in order to characterize effects on the endocrine system observed
in animal studies. Whether ER␣ binding studies can reliably predict
the outcome of corresponding in vivo screening assays such as the
uterotrophic assay remains to be explored.

Table 7
Relative binding afﬁnities for reference and test compounds using dimethylsulfoxide as solvent.
Compound

Experiment No.

17␤-Estradiol

Relative binding afﬁnity [%]

Coefﬁcient of variation [%]

100

–

Norethynodrel

E
F
G
Mean ± S.D.

0.2322
0.2318
0.2094
0.2245 ± 0.0131

5.8

Dibutylphthalate

E
F
G
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

–

E
F
G
Mean ± S.D.

0.1324
0.1055
0.1209
0.1196 ± 0.0135

11.3

o,p -DDT

E
F
G
Mean ± S.D.

0.0702
0.0463
0.0625
0.0596 ± 0.0122

20.5

Corticosterone

E
F
G
Mean ± S.D.

No afﬁnity
No afﬁnity
No afﬁnity
–

Genistein



Relative binding afﬁnities were calculated from data given in Table 5.
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Table 8
Kd values for estrogen receptors isolated from various sources.
Estrogen receptor

Expression system

Receptor preparation

Methodologya

Kd [nM]b

Reference

Full length human recombinant ER␣
Full length human recombinant ER␣
Human ER (mainly ␣-subtype) from MCF-7 cells
Human ER (mainly ␣-subtype) from MCF-7 cells
Full length human recombinant ER␣
Human recombinant ER␣–ligand binding domain
Human recombinant ER␣–ligand binding domain
Full length quail recombinant ER␣
Full length alligator recombinant ER␣
Full length salamander recombinant ER␣
Full length fathead minnow recombinant ER␣
Rat ER (mainly ␣-subtype) from rat uterus, laboratory X
Rat ER (mainly ␣-subtype) from rat uterus, laboratory Y
Rat ER (mainly ␣-subtype) from rat uterus, laboratory Z

Insect cells
Insect cells
–
–
Yeast
Yeast
Bacteria
Insect cells
Insect cells
Insect cells
Insect cells
–
–
–

Puriﬁed protein
Extract
Cytosol
Cell extract
Yeast extract
Yeast extract
Bacteria extract
Extract
Extract
Extract
Extract
Cytosol
Cytosol
Cytosol

Charcoal
Charcoal
Charcoal
No information
No information
No information
No information
Charcoal
Charcoal
Charcoal
Charcoal
Hydroxyapatite
Hydroxyapatite
Hydroxyapatite

0.37
0.22
0.13
0.36
0.35
1.00
1.49
0.58
0.44
0.28
0.58
0.15–1.18
0.04–0.24
0.8–1.5

This investigation
[12]
[19]
[20]
[20]
[20]
[20]
[12]
[12]
[12]
[12]
[16]
[16]
[16]

a
b

Methodology used to separate receptor-bound from unbound ligand.
[3 H]-17␤-estradiol was used as ligand for Kd determinations.

Table 9
Comparison of relative ER␣ binding afﬁnities to published data.
Compound

Investigation
This investigation (full
length human
recombinant) RBA [%]

Rider et al. [12] (full
length human
recombinant) RBA [%]

Kuiper et al. [13] (full
length human
recombinant) RBA [%]

METI/CERI [14] (human
recombinant ligand
binding domain) RBA [%]

Blair et al. [15]
(rat uterus
cytosol) RBA [%]

EPA validation [16]
(rat uterus cytosol)
RBA [%]

17␤-Estradiol
Ethynylestradiol
DES
m-Hexestrol
Norethynodrel
Butylparaben

100
64.5
16.8
4.46
0.247/0.225DMSO
0.00499

100
91.2
Not done
Not done
Not done
Not done

100
Not done
236
Not done
Not done
Not done

100
142
88.9
37.6
0.282
0.018

100
190
400
300
0.204
Not done

Equol
Genistein
Nonylphenol

1.10
0.199/0.120DMSO
0.130

Not done
Not done
Not done

Not done
4/0.7
0.05

Not done
0.12
0.108

Not done
Not done
0.019–0.037

o,p -DDT

0.0689/0.0596DMSO

Not done

0.01

Not done

0.001

Dibutylphthalate
Corticosterone

No afﬁnity
No afﬁnity

Not done
No afﬁnity

Not done
Not done

No IC50 , RBA<0.001
Not done

No afﬁnity
No afﬁnity

100, 100, 100a
165, 268, 113
590, 284, equivocalb
345, 2090, 270
0.135, 0.147, 0.130
0.00416, 0.0105,
0.00086
0.0812, 0.0542, 0.039
0.971, 4.81, 0.402
0.125, 0.101,
equivocal
Negative, 14,400,
negative
Not done
0.00103, 2.04,
equivocal

For our data, solvent is ethanol, if not otherwise indicated.
a
Data from three laboratories (X, Y, and Z).
b
Equivocal: displacement of labeled ligand was observed, however, no characteristic binding curve was observed.
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